Parminder Singh

3.0k total citations · 1 hit paper
104 papers, 1.5k citations indexed

About

Parminder Singh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Parminder Singh has authored 104 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 38 papers in Pulmonary and Respiratory Medicine and 33 papers in Surgery. Recurrent topics in Parminder Singh's work include Bladder and Urothelial Cancer Treatments (30 papers), Cancer Immunotherapy and Biomarkers (23 papers) and Prostate Cancer Treatment and Research (23 papers). Parminder Singh is often cited by papers focused on Bladder and Urothelial Cancer Treatments (30 papers), Cancer Immunotherapy and Biomarkers (23 papers) and Prostate Cancer Treatment and Research (23 papers). Parminder Singh collaborates with scholars based in United States, Pakistan and United Kingdom. Parminder Singh's co-authors include Mohammed Milhem, Axel Hauschild, Igor Puzanov, Frances A. Collichio, Jason Chesney, Claus Garbe, Theodore F. Logan, Philip Friedlander, Omid Hamid and Merrick I. Ross and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Parminder Singh

89 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

2017 471 citations Parminder Singh et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Parminder Singh

Since Specialization

Citations

This map shows the geographic impact of Parminder Singh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Parminder Singh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Parminder Singh more than expected).

Fields of papers citing papers by Parminder Singh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Parminder Singh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Parminder Singh. The network helps show where Parminder Singh may publish in the future.

Co-authorship network of co-authors of Parminder Singh

This figure shows the co-authorship network connecting the top 25 collaborators of Parminder Singh. A scholar is included among the top collaborators of Parminder Singh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Parminder Singh. Parminder Singh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Olanzapine for Managing Side Effects From Antiangiogenic Tyrosine-Kinase Inhibitors 2025 ·Journal of Pain and Symptom Management ·(unknown), (unknown), (unknown), Aminah Jatoi, Kathryn J. Ruddy, Jacob J. Orme, Lance C. Pagliaro, Fernando Quevedo, Brian A. Costello, (unknown), Elisabeth I. Heath, Yousef Zakharia, Parminder Singh, Oliver Sartor, (unknown), Elizabeth Cathcart-Rake, Stacy D. D’Andre, (unknown), Daniel S. Childs	0
2	Automated risk stratification in localized prostate cancer using an AI-assisted framework. 2025 ·Journal of Clinical Oncology ·(unknown), Syed Arsalan Ahmed Naqvi, (unknown), (unknown), (unknown), Jack R. Andrews, Alan H. Bryce, (unknown), Haidar Abdul‐Muhsin, Daniel S. Childs, Jacob J. Orme, Chitta Baral, Neeraj Agarwal, Sumanta K. Pal, Abhishek Tripathi, Parminder Singh, Yousef Zakharia, Irbaz Bin Riaz	0
3	Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer 2025 ·Current Oncology Reports ·(unknown), (unknown), Mark D. Tyson, Parminder Singh	2
4	A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183). 2024 ·Journal of Clinical Oncology ·Maha Hussain, Masha Kocherginsky, Parminder Singh, (unknown), Zin Myint, Di Jiang, Elizabeth Wulff‐Burchfield, (unknown), Elad Sharon, Richard Piekarz, Joshua J. Meeks, David James VanderWeele	2
5	Fully Automated Agatston Score Calculation From Electrocardiography-Gated Cardiac Computed Tomography Using Deep Learning and Multi-Organ Segmentation: A Validation Study 2024 ·Angiology ·(unknown), (unknown), (unknown), Sunil Kumar, Sudeep Kumar, Dharmendra Jain, Ashish Verma, Parminder Singh, (unknown), Vikas Gupta, (unknown), (unknown), (unknown), Sudhir Rathore	1
6	Correlation of urinary comprehensive genomic profile with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605. 2024 ·Journal of Clinical Oncology ·(unknown), Melissa Plets, Peter C. Black, Parminder Singh, David J. McConkey, Scott Lucia, Vadim S. Koshkin, Kelly Stratton, Trinity J. Bivalacqua, Wassim Kassouf, Sima P. Porten, Rick Bangs, Catherine M. Tangen, Ian M. Thompson, Joshua J. Meeks, (unknown), Kevin G. Phillips, Vincent T. Bicocca, Trevor G. Levin, Seth P. Lerner	0
7	Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605 2023 ·European Urology ·Peter C. Black, Catherine M. Tangen, Parminder Singh, David J. McConkey, M. Scott Lucia, William T. Lowrance, Vadim S. Koshkin, Kelly Stratton, Trinity J. Bivalacqua, Wassim Kassouf, Sima P. Porten, Rick Bangs, Melissa Plets, Ian M. Thompson, Seth P. Lerner	48
8	Source of funding and enrollment disparity in prostate cancer (PCa) clinical trials. 2023 ·Journal of Clinical Oncology ·Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, (unknown), (unknown), (unknown), (unknown), (unknown), Parminder Singh, Alan H. Bryce	1
9	Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors 2022 ·ESMO Open ·(unknown), Geoffrey I. Shapiro, (unknown), Amit Mahipal, Jason S. Starr, Muhammad Furqan, Parminder Singh, (unknown), Leena Gandhi, Arnab Ghosh, (unknown), (unknown), (unknown), Eyal C. Attar, Mark M. Awad, Lakshmana Das, Ecaterina E. Dumbrava	34
10	Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis 2022 ·Critical Reviews in Oncology/Hematology ·Irbaz Bin Riaz, (unknown), Syed Arsalan Ahmed Naqvi, Huan He, Rabbia Siddiqi, (unknown), (unknown), (unknown), Wenxin Xu, (unknown), Parminder Singh, Thai H. Ho, Mehmet Asım Bilen, Yousef Zakharia, Alan H. Bryce, M. Hassan Murad	5
11	516MO Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies 2021 ·Annals of Oncology ·(unknown), Geoffrey I. Shapiro, Xīn Gào, Amit Mahipal, Jason S. Starr, Muhammad Furqan, Parminder Singh, (unknown), (unknown), (unknown), Eyal C. Attar, Mark M. Awad, Satya Das, Ecaterina E. Dumbrava	1
12	Targeting barriers to wider use of trimodality therapy in localized muscle invasive bladder cancer 2020 ·Urologic Oncology Seminars and Original Investigations ·Leslie K. Ballas, Parminder Singh, Seth P. Lerner	1
13	Systemic therapy in bladder preservation 2020 ·Urologic Oncology Seminars and Original Investigations ·Daniel M. Girardi, Pooja Ghatalia, Parminder Singh, Gopa Iyer, Srikala S. Sridhar, Andrea B. Apolo	12
14	Mediation of the Acute Stress Response by the Skeleton 2019 ·Cell Metabolism ·Julian Meyer Berger, Parminder Singh, Lori Khrimian, Donald A. Morgan, Subrata Chowdhury, Emilio Arteaga‐Solis, Tamás L. Horváth, Ana I. Domingos, Anna L. Marsland, Vijay K. Yadav, Kamal Rahmouni, Xiao‐Bing Gao, Gérard Karsenty	115
15	Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial 2016 ·Annals of Oncology ·T.B. Powles, Bernard Escudier, Paul de Souza, S. Chowdhury, David Pook, Ulrika Harmenberg, Naveen S. Basappa, Daniel M. Geynisman, Jaime R. Merchan, Bruce G. Redman, Christopher W. Ryan, (unknown), Thai H. Ho, Parminder Singh, Julie C. Lougheed, Manali I. Patel, Jennifer J. Knox, Robert J. Motzer, Toni K. Choueiri	1
16	EFFECT OF SELENIUM SUPPLEMENTATION ON PROTEOMIC SERUM BIOMARKERS IN ELDERLY MEN 2015 ·The Journal of Frailty & Aging ·Amit M. Algotar, (unknown), Parminder Singh, Patricia A. Thompson, Chiu‐Hsieh Hsu, Steven P. Stratton	6
17	Sequencing Systemic Therapies for Metastatic Kidney Cancer 2015 ·Current Treatment Options in Oncology ·Parminder Singh, Neeraj Agarwal, Sumanta K. Pal	12
18	PD-1/PD-L1 in Renal Cell Carcinoma: Projecting the Way Forward 2014 ·Clinical Genitourinary Cancer ·Sumanta K. Pal, Parminder Singh, Nicholas J. Vogelzang	2
19	Effect of selection on humoral and in vivo cell mediated immune responses in broiler chicken 2012 ·Indian Journal of Poultry Science ·Parminder Singh, (unknown), (unknown), (unknown)	1
20	Cocaine-Induced Torsades de Pointes in Idiopathic Long Q-T Syndrome 2001 ·American Journal of Therapeutics ·Narpinder Singh, Harinder Singh, Parminder Singh, Ijaz A. Khan	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact